Iksuda Aims For Best-In-Class Cancer ADCs With Toolbox Approach To Technology

 
• By Ayisha Sharma
Emerging Company Profile: Iksuda Therapeutics
PermaLink Can Design ADCs That Are Insusceptible To De-Conjugation • Source: Shutterstock

More from Emerging Company Profiles

More from Start-Ups & SMEs